Stock BTAI BIOXCEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Real-time Estimate Cboe BZX
Other stock markets
 10:51:30 2024-04-25 am EDT 		5-day change 1st Jan Change
2.565 USD -5.35% Intraday chart for BioXcel Therapeutics, Inc. +1.05% -12.65%
Apr. 22 BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment MT
Apr. 22 BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
AQ
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
AQ
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment
MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
AQ
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
CI
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
AQ
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia
CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants
MT
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
AQ
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia
MT
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
AQ
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating
MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating
MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
AQ
North American Morning Briefing : Inflation Data -2-
DJ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
AQ
North American Morning Briefing : Nvidia Ignites -2-
DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. News BioXcel Therapeutics, Inc.